Exomnis Biotech is a Maastricht based start-up company, operating at the intersection of microbiology, engineering and immunology. As a spin-off from Maastricht University, taking advantage of more than 100 years combined experience, we have developed engineered commensal bacteria as "living medicines" with a first focus on immuno-therapeutics for cancer treatments.Our solution employs forefront synthetic biology techniques to genetically engineer anaerobic, spore-forming bacteria (Clostridium Sporogenes) with CRISPR-Cas9 gene editing and allelic exchange technology. These plasmid and antibiotic-free spores become delivery vehicles that secret therpautics only at the core of hypoxic/necrotic tumours.